Cargando…

Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension

BACKGROUND: Circulating angiopoietin-1 (Ang-1) has been linked to pulmonary hypertension (PH) in experimental studies. However, the clinical relevance of Ang-1 as a biomarker in PH remains unknown. We aimed to investigate the prognostic and clinical significance of Ang-1 in PH using data from the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Manuel Jonas, Tiede, Svenja Lena, Sommer, Natascha, Schmidt, Thomas, Seeger, Werner, Ghofrani, Hossein Ardeschir, Schermuly, Ralph, Gall, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089726/
https://www.ncbi.nlm.nih.gov/pubmed/27802345
http://dx.doi.org/10.1371/journal.pone.0165982
_version_ 1782464289159774208
author Richter, Manuel Jonas
Tiede, Svenja Lena
Sommer, Natascha
Schmidt, Thomas
Seeger, Werner
Ghofrani, Hossein Ardeschir
Schermuly, Ralph
Gall, Henning
author_facet Richter, Manuel Jonas
Tiede, Svenja Lena
Sommer, Natascha
Schmidt, Thomas
Seeger, Werner
Ghofrani, Hossein Ardeschir
Schermuly, Ralph
Gall, Henning
author_sort Richter, Manuel Jonas
collection PubMed
description BACKGROUND: Circulating angiopoietin-1 (Ang-1) has been linked to pulmonary hypertension (PH) in experimental studies. However, the clinical relevance of Ang-1 as a biomarker in PH remains unknown. We aimed to investigate the prognostic and clinical significance of Ang-1 in PH using data from the prospectively recruiting Giessen PH Registry. METHODS: Patients with suspected PH (without previous specific pulmonary arterial hypertension [PAH] therapy) who underwent initial right heart catheterization (RHC) in our national referral center between July 2003 and May 2012 and who agreed to optional biomarker analysis were included if they were diagnosed with idiopathic PAH, connective tissue disease-associated PAH (CTD-PAH), PH due to left heart disease (PH-LHD), or chronic thromboembolic PH (CTEPH), or if PH was excluded by RHC (non-PH controls). The association of Ang-1 levels with disease severity (6-minute walk distance and pulmonary hemodynamics) was assessed using linear regression, and the impact of Ang-1 levels on transplant-free survival (primary endpoint) and clinical worsening was assessed using Kaplan—Meier curves, receiver operating characteristic (ROC) analyses, and Cox regression. RESULTS: 151 patients (39, 39, 32, and 41 with idiopathic PAH, CTD-PAH, PH-LHD, and CTEPH, respectively) and 41 non-PH controls were included. Ang-1 levels showed no significant difference between groups (p = 0.8), and no significant associations with disease severity in PH subgroups (p ≥ 0.07). In Kaplan—Meier analyses, Ang-1 levels (stratified by quartile) had no significant impact on transplant-free survival (p ≥ 0.27) or clinical worsening (p ≥ 0.51) in PH subgroups. Regression models found no significant association between Ang-1 levels and outcomes (p ≥ 0.31). ROC analyses found no significant cut-off that would maximize sensitivity and specificity. CONCLUSIONS: Despite a strong pathophysiological association in experimental studies, this first comprehensive analysis of Ang-1 in PH subgroups suggests that Ang-1 is not a predictive and clinically relevant biomarker in PH.
format Online
Article
Text
id pubmed-5089726
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50897262016-11-15 Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension Richter, Manuel Jonas Tiede, Svenja Lena Sommer, Natascha Schmidt, Thomas Seeger, Werner Ghofrani, Hossein Ardeschir Schermuly, Ralph Gall, Henning PLoS One Research Article BACKGROUND: Circulating angiopoietin-1 (Ang-1) has been linked to pulmonary hypertension (PH) in experimental studies. However, the clinical relevance of Ang-1 as a biomarker in PH remains unknown. We aimed to investigate the prognostic and clinical significance of Ang-1 in PH using data from the prospectively recruiting Giessen PH Registry. METHODS: Patients with suspected PH (without previous specific pulmonary arterial hypertension [PAH] therapy) who underwent initial right heart catheterization (RHC) in our national referral center between July 2003 and May 2012 and who agreed to optional biomarker analysis were included if they were diagnosed with idiopathic PAH, connective tissue disease-associated PAH (CTD-PAH), PH due to left heart disease (PH-LHD), or chronic thromboembolic PH (CTEPH), or if PH was excluded by RHC (non-PH controls). The association of Ang-1 levels with disease severity (6-minute walk distance and pulmonary hemodynamics) was assessed using linear regression, and the impact of Ang-1 levels on transplant-free survival (primary endpoint) and clinical worsening was assessed using Kaplan—Meier curves, receiver operating characteristic (ROC) analyses, and Cox regression. RESULTS: 151 patients (39, 39, 32, and 41 with idiopathic PAH, CTD-PAH, PH-LHD, and CTEPH, respectively) and 41 non-PH controls were included. Ang-1 levels showed no significant difference between groups (p = 0.8), and no significant associations with disease severity in PH subgroups (p ≥ 0.07). In Kaplan—Meier analyses, Ang-1 levels (stratified by quartile) had no significant impact on transplant-free survival (p ≥ 0.27) or clinical worsening (p ≥ 0.51) in PH subgroups. Regression models found no significant association between Ang-1 levels and outcomes (p ≥ 0.31). ROC analyses found no significant cut-off that would maximize sensitivity and specificity. CONCLUSIONS: Despite a strong pathophysiological association in experimental studies, this first comprehensive analysis of Ang-1 in PH subgroups suggests that Ang-1 is not a predictive and clinically relevant biomarker in PH. Public Library of Science 2016-11-01 /pmc/articles/PMC5089726/ /pubmed/27802345 http://dx.doi.org/10.1371/journal.pone.0165982 Text en © 2016 Richter et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Richter, Manuel Jonas
Tiede, Svenja Lena
Sommer, Natascha
Schmidt, Thomas
Seeger, Werner
Ghofrani, Hossein Ardeschir
Schermuly, Ralph
Gall, Henning
Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title_full Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title_fullStr Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title_full_unstemmed Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title_short Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
title_sort circulating angiopoietin-1 is not a biomarker of disease severity or prognosis in pulmonary hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089726/
https://www.ncbi.nlm.nih.gov/pubmed/27802345
http://dx.doi.org/10.1371/journal.pone.0165982
work_keys_str_mv AT richtermanueljonas circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT tiedesvenjalena circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT sommernatascha circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT schmidtthomas circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT seegerwerner circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT ghofranihosseinardeschir circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT schermulyralph circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension
AT gallhenning circulatingangiopoietin1isnotabiomarkerofdiseaseseverityorprognosisinpulmonaryhypertension